Here are some Cochrane Reviews for World Cancer Day 2019: https://t.co/AziPgFu5MI https://t.co/Sopf6IyuHe https://t.co/H7AtqBPFDb https://t.co/tHbD1Ne2Ew https://t.co/6unFAXLe0z
RT @CochraneLibrary: Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate c…
Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate cancer but may increase side-effects. https://t.co/SiGF3PDll6 @CochraneUK https://t.co/erG5CWCNg3
RT @CochraneLibrary: Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate c…
RT @CochraneLibrary: Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate c…
RT @CochraneLibrary: Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate c…
Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate cancer but may increase side-effects. https://t.co/SiGF3PDll6 @CochraneUK @PCFnews @ProstateUK @BeatPCa @ProstateCancerC @Prostate_HU @pros
RT @CochraneLibrary: Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate c…
RT @CochraneLibrary: Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate c…
Adding docetaxel to hormone therapy probably improves survival for people with metastatic hormone-sensitive prostate cancer but may increase side-effects. https://t.co/SiGF3PDll6 @CochraneUK https://t.co/b86QHe1KNo
Nueva #revisión de @cochranecollab : “Tratamiento quimiohormonal con taxanos para el cáncer de próstata metastásico sensible a las hormonas” de @CochraneUrology . https://t.co/NrDx7Df2WT.
Congrats to HSC #medlib Gretchen Kuntz for her co-authorship of 2 systematic reviews! One as part of her work on @CDCgov's HICPAC guideline on C. diff in the NICU (https://t.co/oSFeAMXlqz), and the second is a @cochranecollab #SR on prostate cancer (https:
Cochrane Review: Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer https://t.co/iWNorSXBkS #prostatecancer
RT @CochraneUK: New @cochranecollab Review: 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer' from @Coc…
RT @CochraneLibrary: New @cochranecollab Review: 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer' from…
RT @CochraneLibrary: New @cochranecollab Review: 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer' from…
RT @CochraneLibrary: New @cochranecollab Review: 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer' from…
RT @CochraneLibrary: New @cochranecollab Review: 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer' from…
New @cochranecollab Review: 'Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer' from @CochraneUrology https://t.co/SiGF3PDll6 Taxane‐based chemo + hormone therapy likely improves overall & cancer‐specific survival and
RT @gedefo_sefh: "Adding taxane-based chemotherapy to androgen deprivation therapy for the treatment of metastatic hormone-sensitive prosta…
"Adding taxane-based chemotherapy to androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer" https://t.co/Ie0YHYQpPu